GUCY1A2

Across TCGA pan-cancer cohorts, GUCY1A2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GUCY1A2 data layer compared with 22 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher GUCY1A2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GUCY1A2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD, UCEC, and HNSC are the cancer types where GUCY1A2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	III,IV	0.240	0.995	.002	24	view →
UCEC	OS	Median	III,IV	0.433	1.000	.007	24	view →
HNSC	OS	Tertile	II,III,IV	0.951	0.638	.008	21	view →
CCRCC	DFS	Tertile	IV	0.106	0.948	.038	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GUCY1A2–LUAD (DFS)

Open the LUAD breakdown →